Angiogenesis Inhibitors: all 4,430 studies that test it
Page 26 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)CompletedNCT03703167Phase 1
- Lenalidomide in Anti-MAG Neuropathy: Phase 1b StudyTerminatedNCT03701711Phase 1
- Treatment of Colorectal Liver Metastases With Immunotherapy and BevacizumabCompletedNCT03698461Phase 2
- A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell CarcinomaWithdrawnNCT03693573Phase 3
- Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian CancerTerminatedNCT03690739Phase 3
- Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
- Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)CompletedNCT03668054Phase 3
- A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCTerminatedNCT03666728Phase 2
- Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®CompletedNCT03659305Phase 1
- Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT03657420Phase 1
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
- Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent ThalassemiaCompletedNCT03651102Phase 2/3
- Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal CancerStatus unknownNCT03649945Phase 2
- Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsStatus unknownNCT03647956Phase 2
- SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal CancerTerminatedNCT03645876Phase 2
- Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerActive, not recruitingNCT03635021Phase 3
- Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent GlioblastomaStatus unknownNCT03631836Phase 1
- Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular EdemaWithdrawnNCT03629210Phase 2
- Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLCStatus unknownNCT03616691Phase 2
- Endostar Combine With Radiotherapy in Brain Metastasis of NSCLCStatus unknownNCT03614065Phase 2
- Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian CancerStatus unknownNCT03611179Phase 2
- Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical TrialStatus unknownNCT03609307Phase 2/3
- A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationWithdrawnNCT03608501Phase 2
- A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesStatus unknownNCT03607643Phase 1/2
- An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingNCT03606577Phase 2
- Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMStatus unknownNCT03605056Phase 2
- The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing ChemotherapyStatus unknownNCT03601871Not applicable
- Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansStatus unknownNCT03601624Phase 2
- Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian CancerCompletedNCT03596281Phase 1
- Intense Treatment Regimen With Intravitreal Aflibercept InjectionStatus unknownNCT03594461Phase 1/2
- Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line AxitinibStatus unknownNCT03592199Phase 2
- Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
- Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT03590652Phase 2
- Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal LaserCompletedNCT03590444Phase 4
- Effect of Bevacizumab in Metastatic Triple Negative Breast CancerCompletedNCT03577743Phase 2
- Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab TreatmentTerminatedNCT03573986Phase 1
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2
- A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPMCompletedNCT03560973Phase 2
- Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
- A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationActive, not recruitingNCT03556332Phase 2
- SGT-53 in Children With Recurrent or Progressive CNS MalignanciesWithdrawnNCT03554707Early Phase 1
- Single or Combined Protocols for NV-AMDCompletedNCT03552770Phase 4
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingNCT03541902Phase 2
- A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung CancerStatus unknownNCT03533127Phase 3
- Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy ImprovementCompletedNCT03531294Phase 2
- Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCActive, not recruitingNCT03527108Phase 2
- Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerActive, not recruitingNCT03526432Phase 2
- Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple MyelomaTerminatedNCT03520985Phase 2
- RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer PatientsCompletedNCT03520946Phase 3
- A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRCCompletedNCT03511963Phase 3
- XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal CancerStatus unknownNCT03511183Phase 2
- Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaActive, not recruitingNCT03500445Phase 2
- Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous SystemCompletedNCT03495960Phase 2
- To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes MellitusCompletedNCT03495765Phase 3
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male SubjectsCompletedNCT03483649Phase 1
- Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly AfliberceptStatus unknownNCT03468296Phase 4
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic CancerActive, not recruitingNCT03463460Phase 2
- Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva CombinationStatus unknownNCT03462212Phase 1/2
- Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung CancerStatus unknownNCT03461185Phase 2
- Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.Status unknownNCT03458923Phase 4
- Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept InjectionCompletedNCT03453281Phase 4
- Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)Status unknownNCT03452657Phase 3
- Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)Status unknownNCT03449173Phase 2
- A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1
- A Pilot Bioequivalence Study of PomalidomideCompletedNCT03424928Phase 1
- Ziv-aflibercept Efficacy in Better Regulating AMDCompletedNCT03423823Phase 2
- SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to MyopiaCompletedNCT03409250Phase 4
- Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein OcclusionStatus unknownNCT03405376Phase 4
- Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for TransplantationCompletedNCT03402295Phase 3
- Treatment of Macular Edema After Cataract Surgery with Subconjunctival AfliberceptTerminatedNCT03396861Phase 1
- Pre-operative Immunotherapy Combination Strategies in Breast CancerCompletedNCT03395899Phase 2
- Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMDCompletedNCT03393767Phase 4
- A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer PatientsActive, not recruitingNCT03390686Phase 3
- Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular CarcinomaTerminatedNCT03382886Phase 1
- Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal CancerWithdrawnNCT03380689Phase 1
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedNCT03379051Phase 1/2
- ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)WithdrawnNCT03374670Phase 2
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
- BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
- Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT03359460Phase 1
- Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein OcclusionStatus unknownNCT03353324Phase 2/3
- Two Chemotherapy Regimens Plus or Minus BevacizumabActive, not recruitingNCT03351296Phase 2
- EGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideStatus unknownNCT03341494Phase 2
- Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell CarcinomaWithdrawnNCT03323710Phase 2
- Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMDCompletedNCT03312283Phase 1
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
- A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03287908Phase 1
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
- Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based RegimenCompletedNCT03279289Phase 2
- Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaWithdrawnNCT03275558Phase 1
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaActive, not recruitingNCT03269669Phase 2
- Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal CancerWithdrawnNCT03264274Phase 2
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular DegenerationCompletedNCT03249740Phase 1
- The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)CompletedNCT03242460Phase 2
- Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable DiseaseStatus unknownNCT03240549Phase 2
- Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2
- BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).CompletedNCT03227263Phase 3